U-Needle is delighted to announce the appointment of Dr. Gert Veldhuis as Director of U-Needle, effective per January 15, 2018. From that date Mr. Jeroen Wissink, currently Managing Director of U-Needle, and Dr. Veldhuis will together form the Board of Directors of U-Needle.
Amongst other responsibilities, Dr. Veldhuis’ main focus will be on business development. Mr. Wissink will continue to focus on U-Needle’s silicon microneedle products and technology platform.
Dr. Veldhuis brings valuable experience to U-Needle. In 2004 he founded Nanomi (www.nanomi.com), a pharmaceutical company developing complex injectables, manufactured with microfluidic processes. The success of the company led to the acquisition of Nanomi by Lupin Limited, India’s second largest pharmaceutical company, in 2014. At Nanomi, he demonstrated his competence to grow the company and bring new technology successfully to application, while constantly keeping an eye open for new opportunities.
“We are delighted to welcome Gert to our Board of Directors,” said Mr. Wissink, U-Needle’s Founder and Managing Director, on behalf of all current shareholders. “His exceptional business experience in the use of silicon nano/micro technology in the pharmaceutical market, combined with his demonstrated ability to build a successful company, will be of tremendous benefit to U-Needle.”
U-Needle develops proprietary microneedle technology applied in various user-friendly intradermal injection devices for aesthetics, vaccination and diabetes therapies.
The advanced microneedle technology facilitates fast therapy onset and reduced dose in pharmaceutical injectables.